Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-ABY-027
- Development stage
- Preclinical
- Lead developer
- Affibody
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
177Lu-ABY-027 (also known as [177Lu]Lu-ABY-027) is a preclinical-stage therapeutic radiopharmaceutical developed by Affibody AB for the treatment of HER2-expressing cancers, such as breast and ovarian cancers. The molecule is a fusion protein consisting of a second-generation HER2-targeting Affibody molecule (ZHER2:2891) fused to a high-affinity albumin-binding domain (ABD035). It is site-specifically conjugated at the C-terminus with a DOTA chelator and labeled with the beta-emitting radionuclide lutetium-177 (177Lu). The inclusion of the ABD extends the circulatory half-life of the molecule by binding to serum albumin, which prevents glomerular filtration and significantly reduces renal uptake, thereby optimizing the biodistribution profile for targeted radionuclide therapy. Preclinical studies have demonstrated that 177Lu-ABY-027 effectively targets HER2-expressing tumors and extends survival in animal models, both as a monotherapy and in combination with trastuzumab.
- Other names
- [177Lu]Lu-ABY-027ZHER2:2891-ABD035-C-DOTAZHER2:2891-ABD035-DOTA
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 177Lu-ABY-027.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-ABY-027.